论文部分内容阅读
为测定顺铂放射增敏剂量效应,本文时一批放射敏感性中等的体表肿瘤灶,进行对比性研究。肿瘤缩小及消失率对照与试验组分别为62.2%、86.3%(P<0.01);肿瘤消失率二组分别为13.5%、49%(P<0.005)。肿瘤灶≥3cm者,肿瘤消失及缩小率,二组分别为38.5%、83.3%(P<0.01);二组RD_(50)分别为41Gy、26.6Gy,SER为1.54。顺铂并用放射治疗有胃肠道反应及外周血嗜中性粒细胞中等降低。以上结果似表明:顺铂是良好的临床放射增敏剂。但本文观察病例尚少,有必要进一步探讨。
To determine the effect of cisplatin radiation sensitization dose, a batch of tumors with moderate radiosensitivity on body surface were studied in this study. The tumor shrinkage and disappearance rate in the control and experimental groups were 62.2% and 86.3%, respectively (P<0.01). The tumor disappearance rates in the two groups were 13.5% and 49%, respectively (P<0.005). For tumors ≥3cm, tumor disappearance and reduction rate were 38.5% and 83.3% in the two groups (P<0.01); RD_(50) in the two groups were 41Gy and 26.6Gy, respectively; SER was 1.54. Cisplatin combined with radiation therapy has gastrointestinal reactions and moderate reductions in peripheral blood neutrophils. The above results seem to indicate that cisplatin is a good clinical radiosensitizer. However, there are few cases observed in this article and it is necessary to further explore.